Thrombosis – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23053IDB-L5

Select Item

Empower your strategies with our Thrombosis – Drugs In Development, 2024 report and make more profitable business decisions.

Thrombosis is the formation of a blood clot, known as a thrombus, within a blood vessel. This clot can obstruct the normal blood flow, potentially leading to various health complications. Thrombosis can occur in both veins and arteries. Common types include Deep Vein Thrombosis (DVT), where clots form in deep veins, often in the legs, and Pulmonary Embolism (PE), which occurs when a clot dislodges and travels to the lungs. Risk factors for thrombosis include immobility, surgery, certain medical conditions, and genetic factors. Treatment may involve anticoagulant medications to prevent clot formation, and in severe cases, interventions like thrombectomy or placement of a filter in the blood vessel may be considered.

The Thrombosis drugs in development market research report provide comprehensive information on the therapeutics under development for Thrombosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thrombosis and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Thrombosis
Key Targets
· Coagulation Factor XI; Coagulation Factor X; Coagulation Factor XII; Plasminogen; Prothrombin; Plasminogen Activator Inhibitor 1; Antithrombin III; Von Willebrand Factor; Integrin Beta 3; and Integrin Alpha Iib
Key Mechanisms of Action
· Coagulation Factor XI Inhibitor; Coagulation Factor X Inhibitor; Coagulation Factor XII Inhibitor; Plasminogen Activator; Prothrombin Inhibitor; Plasminogen Activator Inhibitor 1 Inhibitor; Von Willebrand Factor Inhibitor; Platelet Glycoprotein VI Inhibitor; Antithrombin III Activator; and Integrin Beta 3 Antagonist
Key Routes of Administration
· Oral; Intravenous; Subcutaneous; Parenteral; Intravenous Bolus; Topical; Transdermal; Intravenous Drip; Intramuscular; and Cutaneous
Key Molecule Types
· Small Molecule; Monoclonal Antibody; Polysaccharide; Recombinant Enzyme; Recombinant Protein; Fusion Protein; Synthetic Peptide; Antisense RNAi Oligonucleotide; Recombinant Peptide; and Peptide
Major Companies
· Bristol-Myers Squibb Co; Jiangsu Hengrui Medicine Co Ltd; Glycan Therapeutics Inc; eXithera Pharmaceuticals Inc; Ionis Pharmaceuticals Inc; Lee's Pharmaceutical Holdings Ltd; Oasis Pharmaceuticals LLC; National Taiwan University; CarboMimetics; and China Resources Pharmaceutical Group Ltd

Scope

  • Therapeutics in Development: Covering 141 molecules, with 118 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Thrombosis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Thrombosis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Thrombosis treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

Acticor Biotech SAS
Addpharma Inc
Alexion Pharmaceuticals Inc
Alfasigma SpA
Alphamab Oncology
Anthos Therapeutics Inc
Antibe Therapeutics Inc
Aplagon Oy
Apmonia Therapeutics SAS
APT Therapeutics Inc
Aronora Inc
Astellas Pharma Inc
Bayer AG
Beijing Kleb Pharmaceutical Development Co Ltd
Beijing Neoletix Biological Technology Co Ltd
Beth Israel Deaconess Medical Center
Bio-Synectics Inc
Bioxodes SA
Bristol-Myers Squibb Co
Cadrenal Therapeutics Inc
Calida Therapeutics
CarboMimetics
Catholic University of Leuven
Central Drug Research Institute
Cereno Scientific AB
Chengdu Shibeikang Biomedical Technology Co Ltd
China Biologic Products Holdings Inc
China Resources Emde Biological Pharmaceutical Co Ltd
China Resources Pharmaceutical Group Ltd
ChoDang Pharm Co Ltd
Chrysalis BioTherapeutics Inc
Cloud Pharmaceuticals Inc
CSL Ltd
CSPC Pharmaceutical Group Ltd
EVAS Therapeutics LLC
eXithera Pharmaceuticals Inc
FunPep Co Ltd
GLSynthesis Inc
Glycan Therapeutics Inc
Guangzhou Dazhou Biomedical Technology Co Ltd
Guangzhou General Pharmaceutical Research Institute Co Ltd
Guangzhou Recomgen Biotech Co Ltd
Hangzhou Adamerck Pharmlabs Inc
Harvard Medical School
HEC Pharma Co Ltd
Hefei Medical & Pharmaceutical Co Ltd
HKND YB1 Pharmaceutical Ltd
Indiana Lysis Technologies LLC
Ionis Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
Jiangxi Jemincare Group Co Ltd
Jubilant Therapeutics Inc
Kalvista Pharmaceuticals Inc
KLUS Pharma Inc
Kolmar Korea Co Ltd
Laboratorios Farmaceuticos Rovi SA
Lee's Pharmaceutical Holdings Ltd
Lunac Therapeutics Ltd
Marizyme Inc
MDI Therapeutics Inc
Merck & Co Inc
Monash University
Mudanjiang Youbo Pharmaceutical Co Ltd
National Taiwan University
Nippon Shinyaku Co Ltd
North China Pharmaceutical Co Ltd
Oasis Pharmaceuticals LLC
Overseas Pharmaceuticals Ltd
Peel Therapeutics Inc
Protheragen Inc
Prothix BV
Quercis Pharma AG
R-Pharm
RedHill Biopharma Ltd
Regeneron Pharmaceuticals Inc
Samjin Pharm Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Institute of Materia Medica Chinese Academy of Sciences
Shenyang Pharmaceutical University
Shenzhen Salubris Pharmaceuticals Co Ltd
Shimao Tianjie Pharmaceutical (Jiangsu) Co Ltd
Shin Poong Pharm Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Signablok Inc
Sirius Therapeutics Inc
Sirnaomics Ltd
Southern Medical University
St. Vincent Hospital
Sujana Biotech
LLC
SupraGen LLC
Suzhou Ribo Life Sciences Co Ltd
Taho Pharmaceuticals Ltd
Takeda Pharmaceutical Co Ltd
Targeted Therapeutic Solutions LLC
Techfields Pharma Co Ltd
The Hospital for Sick Children
Thomas Jefferson University
Tianjin Pharmaceuticals Group Co Ltd
Translational Sciences Inc
University of California Irvine
University of Colorado
University of Illinois at Chicago
University of Liege
University of North Carolina at Chapel Hill
University of Pennsylvania
University of Queensland
University of Sao Paulo
Veralox Therapeutics Inc
Verseon Corp
Virginia Commonwealth University
Vivozon Inc
X-37 LLC
Zehna Therapeutics LLC
Zerion Pharma AS
Zhejiang Hisun Pharmaceutical Co Ltd
Zonhon Biopharma Institute Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Thrombosis reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Thrombosis – Drugs In Development, 2024 in real time.

  • Access a live Thrombosis – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more